Breast cancer patients who message their doctors about certain topics are more likely to discontinue hormone therapy than others, enabling doctors to better predict which patients are at risk of stopping their treatment early.
News: Breast Cancer
Immunotherapies that take off the “brakes” on the adaptive anti-tumor response have worked well in melanoma and lung cancer but less so in breast cancers. That could change.
Jeremy Warner, MD, MS, associate professor of Medicine and Biomedical Informatics, has been awarded a $1 million grant from the National Cancer Institute to develop software that will help clinicians keep up with the increasing complexity of cancer care.
A recent study in the journal Cancer Research demonstrates that a RIG-I agonist has potent immunogenic and therapeutic effects in breast cancer.
Beyond the usual care she provides her patients in the Palliative Care Unit, Megan Palmer, RN, also connects with them through her music.
A recent study by Rachelle Johnson, Ph.D., and colleagues looked at factors influencing the ability of breast cancer cells to colonize bone and enter and exit a dormant state.
Charles Caskey, Ph.D., has received a cancer research grant from The Mary Kay Foundation to study how focused ultrasound therapy could be an ideal helper for immunotherapy.
Vanderbilt-Ingram Cancer Center (VICC) investigators have received financial support from Susan G. Komen for breast cancer research.
Mia Levy, MD, PhD, director of Cancer Health Informatics and Strategy at Vanderbilt-Ingram Cancer Center (VICC) and Ingram Associate Professor of Cancer Research, has been named director of Rush University Cancer Center and Systems Vice President for Cancer Service at Rush University Medical Center in Chicago.
Singer Anita Cochran had famous friends in the room when she celebrated her last cancer treatment, but the person with her who mattered the most was her 89-year-old father.